Skip to main content
. 2014 Aug 8;5:130. doi: 10.3389/fendo.2014.00130

Table 1.

Clinical characteristics of the healthy control subjects and T2DM patients participating the study.

Variable Units Healthy controls (N = 273)
T2DM patients (N = 199)
pa
Median (50% CI) n (males, %) Median (50% CI) n (males, %)
Age Years 62 (54–70) 273 (38) 66 (59–71) 199 (44) **
Duration of diabetes Years 8 (4–12) 199 (44)
BMI kg/m2 26.5 (23.9–29.9) 268 (38) 29.5 (26.2–33.7) 191 (45) ***
BGL mmol/l 4.8 (4.3–5.3) 267 (38) 7.2 (5.7–10.2) 189 (44) ***
HbA1c % 5.6 (5.4–5.8) 77 (36) 6.8 (6.2–7.6) 121 (43) ***
mmol/mol 38 (36–40) 77 (36) 51 (44–60) 121 (43) ***
Total cholesterol (TC) mmol/l 5.1 (4.6–5.7) 178 (36) 4.4 (3.5–5.3) 118 (47) ***
LDL mmol/l 3.1 (2.6–3.5) 115 (34) 2.4 (1.6–3.1) 103 (48) ***
HDL mmol/l 1.4 (1.1–1.7) 172 (35) 1.2 (1.0–1.4) 115 (49) ***
Triglyceride mmol/l 1.0 (0.8–1.6) 127 (35) 1.6 (1.1–2.2) 112 (47) ***
TC/HDL 3.6 (3.0–4.6) 172 (35) 3.6 (3.0–4.2) 115 (49) N.S.
SBP mmHg 126 (118–140) 269 (38) 132 (125–145) 198 (44) ***
DBP mmHg 79 (70–83) 269 (38) 79 (71–84) 198 (44) N.S.
Medicationb
 Anti-hypertensive 63 (30) 139 (40) ***
 Antidepressant 17 (18) 19 (32) N.S.
 Anti-cholesterol 8 (25) 22 (68) **

***p ≤ 0.0001; **p ≤ 0.001; *p ≤ 0.027.

Values are expressed as Median (50% confidence interval).

aMann–Whitney U test for the difference between control subjects and T2DM patients.

bNumber of subjects using one or more of the listed medication types (the difference between the groups evaluated using cross-tabulation and Chi-squared statistics).